Leading Growth Driver in the Congenital Heart Disease (CHD) Market in 2025: Maternal Diabetes Driving Congenital Heart Disease Market Growth Driver's Influence

What Are the Market Size and Growth Forecast for the Congenital Heart Disease (CHD) Market?
The market size for congenital heart disease (CHD) has seen a rapid expansion in the recent years. It's projected to increase from $4.42 billion in 2024 to $4.87 billion in 2025, marking a compound annual growth rate (CAGR) of 10.1%. Factors contributing to the growth during the historical period include a rise in risk factors like obesity and smoking, advancements in diagnostic technologies, growth in the elderly population, heightened awareness campaigns, improved reimbursement policies, and additional funding for research and development.

The market size for congenital heart disease (CHD) is anticipated to experience robust expansion in the upcoming years, escalating to $7.05 billion by 2029 with a compound annual growth rate (CAGR) of 9.7%. The predicted growth in the forecast period can be linked to the increasing availability of healthcare services in emerging regions, ongoing advancements in cardiac imaging technology, rising campaigns encouraging early diagnosis and intervention, increasing worldwide healthcare expenditure, and the emergence of personalized medicine. Key trends within the forecast period comprise the adoption of minimally invasive surgery methods, the growing utilization of telemedicine for distant patient monitoring and counseling, escalating demand for tailored treatment strategies, the invention of state-of-the-art implantable devices boasting improved functionality and durability, and the incorporation of artificial intelligence and machine learning into diagnostic and therapeutic procedures.

What Is Contributing to the Growth of the Congenital Heart Disease (CHD) Market?
The rise in cases of maternal diabetes is predicted to stimulate the expansion of the congenital heart disease (CHD) market. Maternal diabetes or gestational diabetes mellitus (GDM) is a condition that develops during pregnancy in women who were previously not diabetic. Lifestyle alterations, such as sedentary conduct and unhealthy eating practices, in addition to an overall increase in obesity rates among women of reproductive age, lead to maternal diabetes. This condition can result in newborns having congenital heart disease (CHD), as the elevated glucose levels in the mother's blood can affect the heart's development in the fetus. High blood sugar in the mother can interfere with the baby's heart's regular development, thereby escalating the CHD risk. In October 2023, for example, the National Health Service, a UK government department, reported that adverse pregnancy outcomes among women diagnosed with type 2 diabetes was 4.9% in 2021, which saw a rise to 6.6% in 2022. Hence, the surge in maternal diabetes cases is contributing to the upswing of the congenital heart disease (CHD) market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

Which Key Market Leaders Are Driving Congenital Heart Disease (CHD) Industry Growth?
Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

What Are the Emerging Trends in the Congenital Heart Disease (CHD) Industry?
Major firms in the congenital heart disease market are focusing on the development of non-surgical heart valves in a bid to enhance patient results and their overall well-being. Transcatheter or non-surgical heart valves, medical appliances capable of addressing heart valve ailments without the necessity for traditional open-heart procedures, are at the forefront. In February 2023, for example, Medtronic, a medical tech firm from the US, re-launched its Harmony Transcatheter Pulmonary Valve (TPV) System. This pioneering, minimally invasive alternative to open-heart surgery caters to congenital heart disease patients, specifically those suffering from anomalies in their native or surgically repaired right ventricular outflow tract (RVOT). Notably, this system marks the first FDA-approved valve tailored for the right side, offering a non-surgical option to patients enduring severe pulmonary valve regurgitation. The Harmony TPV System, which won the U.S. FDA's approval in 2021, was reintroduced post a voluntary recall, reflecting Medtronic's commitment to continually advance congenital heart disease solutions.

What Are the Main Segments in the Congenital Heart Disease (CHD) Market?
The congenital heart disease (CHD) market covered in this report is segmented -

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types
2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis
3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications
4) By Age Group: Infants, Children, Adolescents, Adults
5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:
1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation
2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)
3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus
4) By Other Types: Single Ventricle Defects, Ebstein's Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Geographic Area Leads the Congenital Heart Disease (CHD) Market?
North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Congenital Heart Disease (CHD) Global Market Report?

- Market Size Analysis: Analyze the Congenital Heart Disease (CHD) Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Congenital Heart Disease (CHD) Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Congenital Heart Disease (CHD) Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Congenital Heart Disease (CHD) Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15545

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.